Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. Bardia A, et al. Among authors: lee ks. Future Oncol. 2024 Mar;20(8):423-436. doi: 10.2217/fon-2023-0188. Epub 2023 Jun 30. Future Oncol. 2024. PMID: 37387213
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW. Im SA, et al. Among authors: lee ks, lee es. Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18. Breast Cancer Res Treat. 2012. PMID: 22094934 Clinical Trial.
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY. Han SW, et al. Among authors: lee ks. PLoS One. 2012;7(7):e39943. doi: 10.1371/journal.pone.0039943. Epub 2012 Jul 27. PLoS One. 2012. PMID: 22848366 Free PMC article. Clinical Trial.
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Ahn JS, Im YH. Park YH, et al. Among authors: lee ks, lee mh, lee s. J Clin Oncol. 2013 May 10;31(14):1732-9. doi: 10.1200/JCO.2012.45.2490. Epub 2013 Apr 8. J Clin Oncol. 2013. PMID: 23569309 Clinical Trial.
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS; Korean Cancer Study Group (KCSG); Im YH. Park YH, et al. Among authors: lee ks, lee mh, lee s. Breast Cancer Res Treat. 2015 Jul;152(1):77-85. doi: 10.1007/s10549-015-3450-z. Epub 2015 Jun 2. Breast Cancer Res Treat. 2015. PMID: 26033708 Clinical Trial.
Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane.
Koh HK, Shin KH, Kim K, Lee ES, Park IH, Lee KS, Ro J, Jung SY, Lee S, Kim SW, Kang HS, Chie EK, Han W, Noh DY, Lee KH, Im SA, Ha SW. Koh HK, et al. Among authors: lee ks, lee kh, lee es, lee s. Cancer Res Treat. 2016 Apr;48(2):483-90. doi: 10.4143/crt.2015.111. Epub 2015 Jun 5. Cancer Res Treat. 2016. PMID: 26044160 Free PMC article.
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Kim SH, Jung KH, Kim TY, Im SA, Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ, Lee S, Sohn JH, Park YH, Im YH, Ahn JH, Kim SB, Kim JH. Kim SH, et al. Among authors: lee ks, lee s. Cancer Res Treat. 2016 Oct;48(4):1373-1381. doi: 10.4143/crt.2015.475. Epub 2016 Mar 23. Cancer Res Treat. 2016. PMID: 27034147 Free PMC article.
6,178 results